Pfizer has sued Watson Laboratories to delay generic Viagra, leveraging the Hatch-Waxman Act and its patents. This case examines Pfizer’s legal strategy and the implications for generic competition in the pharmaceutical market.
Read more about Patent Suit over ViagraTag: Hatch Waxman Act
Pharmaceutical Business Strategy – A Brand Name Perspective
The post explores how brand name drug companies exploit regulatory provisions to maintain market dominance during generic drug challenges. It details the legal and procedural mechanisms involved, focusing on the strategic use of the 30 month stay period under the Hatch Waxman Act.
Read more about Pharmaceutical Business Strategy – A Brand Name PerspectivePharmaceutical Business Strategy – A Generics Perspective
This article examines the strategy of generic drug companies in challenging pharmaceutical patents, focusing on Paragraph IV certifications and related litigation. It highlights trends, success rates, and the increasing participation of Indian companies in the US generics market.
Read more about Pharmaceutical Business Strategy – A Generics Perspective